Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds…
After One Year Of Regulatory Hold, Larimar’s Ataxia Candidate Sees Some Hope
The FDA has cleared the initiation of Larimar Therapeutics Inc’s (NASDAQ:LRMR) 25 mg cohort of Phase 2 trial of CTI-1601 in Friedreich’s…
Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal
Altimmune Inc (NASDAQ:ALT) shares plunged after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty…
Pfizer Starts Pivotal Phase 3 Study of mRNA-Based Influenza Vaccine
Pfizer Inc (NYSE:PFE) has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine…
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
Bayer AG (OTC:BAYRY) has started a hunt for CEO Werner Baumann’s successor, Bloomberg News reported, citing people close to the…
Tencent Music Pushes Hong Kong Listing As Soon As Next Week: Report
Tencent Music Entertainment Group (NYSE:TME) is working with advisers on the preparations for its second listing in Hong Kong,…
NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer
NGM Biopharmaceuticals Inc (NASDAQ:NGM) announced updated preliminary findings from its Phase 1b dose escalation trial of NGM120 in metastatic pancreatic cancer.…
Biden Administration Pushes ‘Cancer Moonshot’ Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."
The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati
Vaxxinity Starts Dosing In Phase 1 Migraine Vaccine Trial
Vaxxinity Inc (NASDAQ:VAXX) announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine…